Despite the largest export of diagnostic kits ever, we canno

Last year's exports hit 4.3 trillion won

Turned to Decline in the Second Half of the Year

Average monthly exports, $440 million in the first half → $120 million drop in the second half

Exports of domestic diagnostic kits broke the record last year.

 

However, export performance in the second half of the year is on the decline.

 

Analysts say that as the global COVID-19 situation calms down, exports of diagnostic kits, which have been on a high march, are returning to the level of previous years.

 

According to the Korea Customs Service on the 16th, exports of diagnostic kits in Korea amounted to USD 3.34908 billion last year.

 

It increased 63.6% from $2.047.32 billion in 2021.

 

This is the highest performance ever.

 

Domestic diagnostic kits have grown rapidly with the spread of COVID-19.

 

Exports of diagnostic kits, which stood at only $253.26 million until 2019, rose vertically to $2.170.87 billion in 2020.

 

It then recorded $2.047.32 billion in 2021.

 

In the first half of last year, export performance increased further.

 

Early last year, the average monthly exports soared to $435 million due to the simultaneous resurgence of COVID-19 around the world.

 

Exports of diagnostic kits also plunged as the global COVID-19 crisis has subsided since the second half of last year.

 

The average monthly export of diagnostic kits in the second half of last year was only $123 million.

 

As the global pandemic is nearing an end, it is predicted that the export performance of diagnostic kits will also return to the level of previous years.

 

Major diagnostic kit companies are also coming up with various measures to prepare for a decrease in global demand.

 

SD Biosensor focused on expanding its appearance and entering the global market through mergers and acquisitions.

 

In July last year, it announced that it would acquire Meridian Bioscience, a U.S.

 

in vitro diagnostic company, for 2 trillion won.

 

The acquisition will be jointly carried out by SD Biosensor and private equity fund operator SJL Partners.

 

SD Biosensor and SJL Partners will take over at a rate of 60% and 40% respectively and invest in Columbus Holding Company, a special purpose corporation (SPC) jointly established in the United States.

 

Madeira Acquisition and Meridian, SPC subsidiaries 100% of Columbus Holding Company, merge and enter Columbus subsidiary.

 

SD BioSensor has been steadily expanding its global distribution network since last year.

 

On top of that, the acquisition of Meridian made it official to enter the world's largest diagnostic market and focused on expanding the global distribution network.

 

On top of that, the company plans to further expand its global territory through additional acquisitions.

 

Seegene is focusing on developing diagnostic kits other than COVID-19.

 

Seegene is developing reagents and equipment that diagnose diseases other than COVID-19 through massive R&D expansion.

 

They include reagents for diagnosing cervical cancer (HPV), sexual intervention (STI), and respiratory diseases other than COVID-19.